You can buy or sell Jaguar Health and other stocks, options, ETFs, and crypto commission-free!
Jaguar Health, Inc. engages in the dvelopment of gastrointestinal products for both human prescription use and animals. Its products include Mytesi, Canalevia, Equilevia, and Neonorm. Read More The Mytesi product IS use for relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Canalevia product is intended for treatment of diarrhea in dogs. The Equilevia product is a non-prescription product for gut health in equine athletes. The Neonorm product is a non-prescription animal products. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
San Francisco, California
52 Week High
52 Week Low
Stock Price, News, & Analysis for Jaguar Health
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical tria...
Simply Wall StFeb 22
Did You Manage To Avoid Jaguar Health’s Devastating 89% Share Price Drop?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! As every investor would know, you don’t hit a homerun every time you swing. But it would be foolish to simply accept every extremely large loss as an inevitable part of the game. It must have been painful to be a Jaguar Health, Inc. (NASDAQ:JAGX) shareholder over the last year, since the stock price plummeted 89% in that time. A loss like this is a stark reminder that portfolio diversification i...